DBV Technologies S.A.
DBVTDBV Technologies S.A. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapy solutions for the treatment of food allergies. The company's flagship product, Viaskin, uses a patch-based delivery system aimed at desensitizing patients to specific allergens, particularly peanut allergies. Founded in France, DBV Technologies aims to address unmet medical needs through its proprietary epicutaneous immunotherapy platform.
Company News
DBV Technologies has filed a new S-3ASR registration statement with the SEC to renew its at-the-market (ATM) offering program for up to $150 million in American Depositary Shares (ADSs). The company plans to use proceeds primarily for manufacturing capacity expansion, pediatric BLA submissions for peanut allergy treatment, and product development...
DBV Technologies announced it has completed extensive discussions with the FDA regarding its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4-7 years. The FDA did not request additional data, but DBV will incorporate feedback on data organization and formatting before submitting the BLA in Q3 2026.
DBV Technologies announced it has completed in-depth discussions with the FDA regarding the Biologics License Application (BLA) for VIASKIN® Peanut patch for children aged 4-7 years. The FDA did not request additional data, and DBV plans to submit the BLA in Q3 2026 after incorporating FDA feedback on data organization and structuring for CMC an...
DBV Technologies announced that CEO Daniel Tassé will not participate in the previously scheduled fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, due to unavoidable travel disruption. The company will still participate in 1-on-1 investor meetings at the event in Miami, FL.
DBV Technologies announced that its management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 in Miami. However, CEO Daniel Tassé will not participate in the planned informal discussion due to unexpected travel disruptions.
